Verve Therapeutics

About:

Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.

Twitter/X: VerveTx

Top Investors: RA Capital Management, Eli Lilly, Wellington Management, F-Prime Capital, ARCH Venture Partners

Description:

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Total Funding Amount:

$419M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2018-01-01

Founders:

Anthony Philippakis, Barry Ticho, Burt Adelman, Issi Rozen, J. Keith Joung, Kiran Musunuru, Sekar Kathiresan

Number of Employees:

101-250